Ascendis Pharma (ADR) (ASND)
Builds and commercializes rare-endocrinology medicines through the TransCon prodrug platform.
$232.65
vs last close−4.93 (−2.07%)
Something off on this page? Send us feedback.
Next report
Nov 11, 26
in 49 days
EPS estimate
$1.13
Revenue estimate
$478.5M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported−$0.68−$1.66−$0.93−$1.17−$0.64$0.32$3.29Pending
Estimate−$1.20−$1.56−$1.42−$0.41−$0.06$0.19$1.71$1.13
Surprise+43.3%−6.4%+34.5%−185.4%−966.7%+70.6%+92.4%—
RevenueReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported$180.1M$110.7M$186.1M$250.2M$344.8M$284.9M$387.5MPending
Estimate$125.4M$153.5M$233.1M$302.6M$292.3M$308.9M$376.8M$478.5M
Surprise+43.6%−27.9%−20.2%−17.3%+18.0%−7.8%+2.8%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2027 | $3.12 | — | — |
| Sep 2027 | $2.46 | — | — |
| Jun 2027 | $2.23 | — | — |
| Mar 2027 | $1.76 | — | — |
| Dec 2026 | $1.09 | — | — |
| Nov 2026 | $1.13 | — | — |
| Aug 2026 | $1.71 | $3.29 | +92.4% |
| May 2026 | $0.19 | $0.32 | +70.6% |
| Feb 2026 | −$0.06 | −$0.64 | −966.7% |
| Nov 2025 | −$0.41 | −$1.17 | −185.4% |
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Sep 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Sep 2023 | |||
| Apr 2023 | |||
| Feb 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Dec 2020 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Apr 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Apr 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Mar 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Mar 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Dec 2015 | |||
| Nov 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2027 | $3.12 | — | — | $601.4M | — | — | — |
| Sep 2027 | $2.46 | — | — | $534.6M | — | — | — |
| Jun 2027 | $2.23 | — | — | $491.9M | — | — | — |
| Mar 2027 | $1.76 | — | — | $434.8M | — | — | — |
| Dec 2026 | $1.09 | — | — | $409.9M | — | — | — |
| Nov 11, 2026 | $1.13 | — | — | $478.5M | — | — | — |
| Aug 13, 2026 | $1.71 | $3.29 | +92.4% | $376.8M | $387.5M | +2.8% | −3.6% |
| May 7, 2026 | $0.19 | $0.32 | +70.6% | $308.9M | $284.9M | −7.8% | +4.3% |
| Feb 11, 2026 | −$0.06 | −$0.64 | −966.7% | $292.3M | $344.8M | +18.0% | −1.5% |
| Nov 12, 2025 | −$0.41 | −$1.17 | −185.4% | $302.6M | $250.2M | −17.3% | +3.6% |
| Aug 7, 2025 | |||||||
| May 1, 2025 | |||||||
| Feb 12, 2025 | |||||||
| Nov 14, 2024 | |||||||
| Sep 3, 2024 | |||||||
| May 2, 2024 | |||||||
| Feb 7, 2024 | |||||||
| Nov 7, 2023 | |||||||
| Sep 5, 2023 | |||||||
| Apr 27, 2023 | |||||||
| Feb 16, 2023 | |||||||
| Nov 2, 2022 | |||||||
| Aug 10, 2022 | |||||||
| May 11, 2022 | |||||||
| Mar 2, 2022 | |||||||
| Nov 10, 2021 | |||||||
| Aug 25, 2021 | |||||||
| May 27, 2021 | |||||||
| Mar 10, 2021 | |||||||
| Dec 31, 2020 | |||||||
| Nov 11, 2020 | |||||||
| Aug 27, 2020 | |||||||
| May 19, 2020 | |||||||
| Apr 1, 2020 | |||||||
| Nov 18, 2019 | |||||||
| Aug 28, 2019 | |||||||
| May 30, 2019 | |||||||
| Apr 3, 2019 | |||||||
| Nov 28, 2018 | |||||||
| Aug 29, 2018 | |||||||
| May 30, 2018 | |||||||
| Mar 28, 2018 | |||||||
| Nov 16, 2017 | |||||||
| Aug 18, 2017 | |||||||
| May 23, 2017 | |||||||
| Mar 22, 2017 | |||||||
| Nov 30, 2016 | |||||||
| Aug 31, 2016 | |||||||
| May 19, 2016 | |||||||
| Dec 31, 2015 | |||||||
| Nov 12, 2015 |